FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242885743> ?p ?o ?g. }

• W4242885743 abstract "Gestational trophoblastic neoplasia (GTN) is a highly curable group of pregnancy-related tumours; however, approximately 25% of GTN tumours will be resistant to, or will relapse after, initial chemotherapy. These resistant and relapsed lesions will require salvage chemotherapy with or without surgery. Various salvage regimens are used worldwide. It is unclear which regimens are the most effective and the least toxic.To determine which chemotherapy regimen/s for the treatment of resistant or relapsed GTN is/are the most effective and the least toxic.We searched the Cochrane Gynaecological Cancer Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 4), MEDLINE and EMBASE up to October 2011. In addition, we handsearched the relevant society conference proceedings and study reference lists.Only randomised controlled trials (RCTs) were included.We designed a data extraction form and planned to use random-effects methods in Review Manager 5.1 for meta-analyses.The search identified no RCTs; therefore we were unable to perform any meta-analyses.RCTs in GTN are scarce owing to the low prevalence of this disease and its highly chemosensitive nature. As chemotherapeutic agents may be associated with substantial side effects, the ideal treatment should achieve maximum efficacy with minimal side effects. For methotrexate-resistant or recurrent low-risk GTN, a common practice is to use sequential five-day dactinomycin, followed by MAC (methotrexate, dactinomycin, cyclophosphamide) or EMA/CO (etoposide, methotrexate, dactinomycin, cyclophosphamide, vinblastine) if further salvage therapy is required. However, five-day dactinomycin is associated with more side effects than pulsed dactinomycin, therefore an RCT comparing the relative efficacy and safety of these two regimens in the context of failed primary methotrexate treatment is desirable.For high-risk GTN, EMA/CO is the most commonly used first-line therapy, with platinum-etoposide combinations, particularly EMA/EP (etoposide, methotrexate, dactinomycin/etoposide, cisplatin), being favoured as salvage therapy. Alternatives, including TP/TE (paclitaxel, cisplatin/ paclitaxel, etoposide), BEP (bleomycin, etoposide, cisplatin), FAEV (floxuridine, dactinomycin, etoposide, vincristine) and FA (5-fluorouracil (5-FU), dactinomycin), may be as effective as EMA/EP and associated with fewer side effects; however, this is not clear from the available evidence and needs testing in well-designed RCTs. In the UK, an RCT comparing interventions for resistant/recurrent GTN will be very challenging owing to the small numbers of patients with this scenario. International multicentre collaboration is therefore needed to provide the high-quality evidence required to determine which salvage regimen/s have the best effectiveness-to-toxicity ratio in low- and high-risk disease. Future research should include economic evaluations and long-term surveillance for secondary neoplasms." @default.
• W4242885743 created "2022-05-12" @default.
• W4242885743 creator A5003520704 @default.
• W4242885743 creator A5009234043 @default.
• W4242885743 creator A5024050303 @default.
• W4242885743 creator A5055280881 @default.
• W4242885743 creator A5056335210 @default.
• W4242885743 creator A5084423190 @default.
• W4242885743 date "2012-12-12" @default.
• W4242885743 modified "2023-09-30" @default.
• W4242885743 title "Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia" @default.
• W4242885743 cites W1519509561 @default.
• W4242885743 cites W1546839557 @default.
• W4242885743 cites W1955563698 @default.
• W4242885743 cites W1967456406 @default.
• W4242885743 cites W1968159849 @default.
• W4242885743 cites W1968373373 @default.
• W4242885743 cites W1973061092 @default.
• W4242885743 cites W1975227644 @default.
• W4242885743 cites W1980610432 @default.
• W4242885743 cites W1983758373 @default.
• W4242885743 cites W1986857398 @default.
• W4242885743 cites W1990388163 @default.
• W4242885743 cites W1995973983 @default.
• W4242885743 cites W1996258414 @default.
• W4242885743 cites W2007830465 @default.
• W4242885743 cites W2010443570 @default.
• W4242885743 cites W2012559637 @default.
• W4242885743 cites W2013314217 @default.
• W4242885743 cites W2021198554 @default.
• W4242885743 cites W2022350079 @default.
• W4242885743 cites W2025484500 @default.
• W4242885743 cites W2028063483 @default.
• W4242885743 cites W2029502978 @default.
• W4242885743 cites W2046229506 @default.
• W4242885743 cites W2051629412 @default.
• W4242885743 cites W2063756180 @default.
• W4242885743 cites W2075642745 @default.
• W4242885743 cites W2078820773 @default.
• W4242885743 cites W2091038119 @default.
• W4242885743 cites W2093685655 @default.
• W4242885743 cites W2093815392 @default.
• W4242885743 cites W2095818528 @default.
• W4242885743 cites W2102748927 @default.
• W4242885743 cites W2107328434 @default.
• W4242885743 cites W2109182864 @default.
• W4242885743 cites W2139151415 @default.
• W4242885743 cites W2149507707 @default.
• W4242885743 cites W2150831746 @default.
• W4242885743 cites W2152552894 @default.
• W4242885743 cites W2158806480 @default.
• W4242885743 cites W2160168356 @default.
• W4242885743 cites W4206066015 @default.
• W4242885743 cites W4251866680 @default.
• W4242885743 cites W4252434684 @default.
• W4242885743 doi "https://doi.org/10.1002/14651858.cd008891.pub2" @default.
• W4242885743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23235667" @default.
• W4242885743 hasPublicationYear "2012" @default.
• W4242885743 type Work @default.
• W4242885743 citedByCount "17" @default.
• W4242885743 countsByYear W42428857432013 @default.
• W4242885743 countsByYear W42428857432015 @default.
• W4242885743 countsByYear W42428857432016 @default.
• W4242885743 countsByYear W42428857432017 @default.
• W4242885743 countsByYear W42428857432018 @default.
• W4242885743 countsByYear W42428857432019 @default.
• W4242885743 countsByYear W42428857432021 @default.
• W4242885743 countsByYear W42428857432022 @default.
• W4242885743 countsByYear W42428857432023 @default.
• W4242885743 crossrefType "reference-entry" @default.
• W4242885743 hasAuthorship W4242885743A5003520704 @default.
• W4242885743 hasAuthorship W4242885743A5009234043 @default.
• W4242885743 hasAuthorship W4242885743A5024050303 @default.
• W4242885743 hasAuthorship W4242885743A5055280881 @default.
• W4242885743 hasAuthorship W4242885743A5056335210 @default.
• W4242885743 hasAuthorship W4242885743A5084423190 @default.
• W4242885743 hasConcept C126322002 @default.
• W4242885743 hasConcept C141071460 @default.
• W4242885743 hasConcept C143998085 @default.
• W4242885743 hasConcept C153911025 @default.
• W4242885743 hasConcept C168563851 @default.
• W4242885743 hasConcept C2776694085 @default.
• W4242885743 hasConcept C2776695378 @default.
• W4242885743 hasConcept C2776755627 @default.
• W4242885743 hasConcept C2778119113 @default.
• W4242885743 hasConcept C2778128677 @default.
• W4242885743 hasConcept C2778336483 @default.
• W4242885743 hasConcept C2779429289 @default.
• W4242885743 hasConcept C2780775027 @default.
• W4242885743 hasConcept C2781413609 @default.
• W4242885743 hasConcept C3675279 @default.
• W4242885743 hasConcept C71924100 @default.
• W4242885743 hasConcept C86803240 @default.
• W4242885743 hasConceptScore W4242885743C126322002 @default.
• W4242885743 hasConceptScore W4242885743C141071460 @default.
• W4242885743 hasConceptScore W4242885743C143998085 @default.
• W4242885743 hasConceptScore W4242885743C153911025 @default.
• W4242885743 hasConceptScore W4242885743C168563851 @default.
• W4242885743 hasConceptScore W4242885743C2776694085 @default.
• W4242885743 hasConceptScore W4242885743C2776695378 @default.

• next